Theravance Biopharma Inc
TBPH | NASDAQ
$17.05
$0 (0.00%)
Sep 22, 2026, 12:33 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
PE Ratio | 8.91 | -8.18 | -11.24 | -8.90 | -3.85 | -3.98 |
PEG Ratio | -0.03 | -0.55 | 0.54 | 0.16 | 0.11 | -0.81 |
PS Ratio | 8.76 | 7.14 | 10.82 | 16.08 | 13.88 | 15.42 |
PB Ratio | 3.17 | 2.62 | 2.92 | 1.87 | -2.27 | -3.65 |
P/FCF Ratio | 3.95 | -38.73 | -21.08 | -4.40 | -3.63 | -4.31 |
P/OCF Ratio | 3.95 | -39.85 | -23.02 | -4.42 | -3.69 | -4.42 |
OCF/S Ratio | 221.97 | -17.92 | -47.01 | -364.18 | -375.80 | -348.47 |
Debt / Equity Ratio | 0.25 | 0.28 | 0.23 | 0.12 | -1.98 | -2.23 |
Quick Ratio | 10.93 | 5.02 | 5.39 | 12.31 | 4.26 | 3.18 |
Current Ratio | 10.93 | 5.02 | 5.39 | 12.31 | 4.26 | 3.18 |
Asset Turnover | 0.22 | 0.18 | 0.15 | 0.08 | 0.15 | 0.15 |
Interest Coverage | -5.38 | -18.44 | -23.84 | -14.44 | -30.16 | -34.82 |
Return on Equity | 35.69% | -32.14% | -25.91% | 197.40% | 58.90% | 91.53% |
Return on Assets | 21.81% | -15.93% | -14.45% | 143.58% | -53.21% | -59.27% |
Return on Invested Capital | -2.37% | -14.11% | -15.52% | -15.71% | -77.21% | -77.20% |
Dividend Yield | n/a | n/a | n/a | n/a | n/a | n/a |
Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
FCF Payout Ratio | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit Margin | 94.87% | 41.53% | 29.26% | -23.46% | -250.12% | 100% |
Net Profit Margin | 98.54% | -87.63% | -96.11% | 1.7K% | -360.55% | -386.90% |
Pretax Profit Margin | 120.27% | -69.30% | -85.80% | -180.76% | -479.51% | -422.15% |
Operating Profit Margin | -12.33% | -72.92% | -97.58% | -179.09% | -466.06% | -414.19% |
FCF Margin | 221.93% | -18.43% | -51.35% | -365.29% | -381.96% | -357.68% |
EBITDA Margin | 127.69% | -59.73% | -89.94% | -148.18% | -420.95% | -400.55% |
Add to Watchlist
Select watchlists to add or remove TBPH